NCT01979445 (BRIDGE) is a Phase 2 clinical trial of Cangrelor in Coronary Artery Disease (CAD), sponsored by The Medicines Company.

Who is sponsoring NCT01979445?

NCT01979445 is sponsored by The Medicines Company.

What drugs are being tested in NCT01979445?

Interventions in NCT01979445: Cangrelor, Clopidogrel, Prasugrel.

What condition does NCT01979445 study?

NCT01979445 studies Coronary Artery Disease (CAD).

Is NCT01979445 still recruiting?

NCT01979445 is currently completed. Last updated 26 February 2020.

Are results published for NCT01979445?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-02-26 · How we verify

NCT01979445: BRIDGE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cangrelor to Clopidogrel or Prasugrel Transition Study

Completed Phase 2 Results posted Last updated 26 February 2020

What this trial tests

Phase 2 trial testing Cangrelor in Coronary Artery Disease (CAD) in 15 participants. Completed in 20 January 2014.

Timeline

2 December 2013

Primary endpoint
20 January 2014

20 January 2014

Quick facts

Lead sponsor	The Medicines Company
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	15
Start date	2 December 2013
Primary completion	20 January 2014
Estimated completion	20 January 2014
Sites	1 location across United States

Drugs / interventions tested

Cangrelor (CANGRELOR) — full drug profile →
Clopidogrel (clopidogrel) — full drug profile →
Prasugrel (PRASUGREL) — full drug profile →

Conditions studied

Coronary Artery Disease (CAD) — all drugs for Coronary Artery Disease (CAD) →

Sponsor

The Medicines Company — full company profile →

Who can join

Adults 18 to 74, any sex, with Coronary Artery Disease (CAD). Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Extent of Preservation Of Platelet Inhibitory Effect After Transition From Cangrelor To Prasugrel Or Clopidogrel Compared With Effect Observed With Prasugrel Or Clopidogrel Alone Primary · Day 1 at 5.5 or 6 hrs after administration of prasugrel or clopidogrel (reference) and Day 1 at 2.25, 2.5, 2.75, 3, 4, and 5.5 hrs after initiation of cangrelor infusion

A reference point for prasugrel or clopidogrel was chosen for comparison and designated at 6 or 5.5 hrs after the administration of prasugrel or clopidogrel as the reference for the effect of the oral drug. Platelet function was assessed using light transmittance aggregometry (LTA). LTA measures the aggregation or cross linking of platelets by fibrinogen and requires the activation of platelets plus the binding of fibrinogen. The extent of aggregation was expressed as % aggregation in response to 20 micromolar (μM) adenosine diphosphate (ADP) at 300 seconds (sec) (final/terminal aggregation re

Prasugrel/Clopidogrel Reference (6 or 5.5 hrs)

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	1.3	± 1.5
Clopidogrel Within 5 Min After Cangrelor	21.7	± 16.4
Clopidogrel 1.5 Hrs During Cangrelor	50.0	± 16.8
Clopidogrel 1 Hr During Cangrelor	50.3	± 15.9

2.25 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	16.3	± 10.1
Clopidogrel Within 5 Min After Cangrelor	26.0	± 7.9
Clopidogrel 1.5 Hrs During Cangrelor	22.2	± 16.0
Clopidogrel 1 Hr During Cangrelor	33.3	± 7.5

2.5 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	60.0	± 7.5
Clopidogrel Within 5 Min After Cangrelor	49.7	± 7.1
Clopidogrel 1.5 Hrs During Cangrelor	54.3	± 11.7
Clopidogrel 1 Hr During Cangrelor	62.0	± 3.6

2.75 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	63.3	± 1.5
Clopidogrel Within 5 Min After Cangrelor	58.3	± 7.4
Clopidogrel 1.5 Hrs During Cangrelor	56.8	± 11.3
Clopidogrel 1 Hr During Cangrelor	67.7	± 1.2

3 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	65.0	± 2.0
Clopidogrel Within 5 Min After Cangrelor	56.0	± 8.9
Clopidogrel 1.5 Hrs During Cangrelor	56.2	± 16.4
Clopidogrel 1 Hr During Cangrelor	65.0	± 9.5

4 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	16.3	± 27.4
Clopidogrel Within 5 Min After Cangrelor	38.0	± 31.7
Clopidogrel 1.5 Hrs During Cangrelor	51.2	± 27.4
Clopidogrel 1 Hr During Cangrelor	62.7	± 8.5

5.5 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	1.3	± 1.5
Clopidogrel Within 5 Min After Cangrelor	26.7	± 20.5
Clopidogrel 1.5 Hrs During Cangrelor	NA	± NA
Clopidogrel 1 Hr During Cangrelor	NA	± NA

Extent Of Preservation Of Platelet Inhibitory Effect Of Cangrelor Treatment After Prasugrel Or Clopidogrel Compared To Treatment With Cangrelor Alone Primary · Day 1 at 1, 1.5, 2, or 2.5 hrs after administration of prasugrel or clopidogrel (reference) and Day 1 at 1.75 and 2 hrs after initiation of cangrelor infusion

A reference point for cangrelor was chosen for comparison and designated as the administration time of prasugrel 60 mg or clopidogrel 600 mg (2.5, 2, 1.5, or 1 hrs). Platelet function was assessed using LTA. LTA measures the aggregation or cross linking of platelets by fibrinogen and requires the activation of platelets plus the binding of fibrinogen. The extent of aggregation was examined using LTA and expressed as % aggregation in response to 20 μM ADP at 300 sec (final/terminal aggregation response).

Cangrelor Reference (2.5, 2, 1.5, or 1 hrs)

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	60.0	± 7.5
Clopidogrel Within 5 Min After Cangrelor	0	± 0
Clopidogrel 1.5 Hrs During Cangrelor	2.0	± 3.5
Clopidogrel 1 Hr During Cangrelor	3.0	± 2.0

1.75 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	0.3	± 0.6
Clopidogrel Within 5 Min After Cangrelor	1.0	± 1.0
Clopidogrel 1.5 Hrs During Cangrelor	1.8	± 2.5
Clopidogrel 1 Hr During Cangrelor	1.3	± 0.6

2 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	0.3	± 0.6
Clopidogrel Within 5 Min After Cangrelor	NA	± NA
Clopidogrel 1.5 Hrs During Cangrelor	1.5	± 2.0
Clopidogrel 1 Hr During Cangrelor	2.3	± 1.2

Extent of Preservation Of Platelet Inhibitory Effect After Transition From Cangrelor to Prasugrel Or Clopidogrel Compared With Effect Observed With Prasugrel Or Clopidogrel Alone Determined By VerifyNow P2Y12 Assay Secondary · Day 1 at 5.5 or 6 hrs after administration of prasugrel or clopidogrel (reference) and Day 1 at 2.25, 2.5, 2.75, 3, 4, and 5.5 hrs after initiation of cangrelor infusion

A reference point for prasugrel or clopidogrel was chosen for comparison and designated at 6 or 5.5 hrs after the administration of prasugrel or clopidogrel as the reference for the effect of the oral drug. Platelet function was assessed using the VerifyNow P2Y12 assay. The VerifyNow P2Y12 assay measures the aggregation or cross linking of platelets by fibrinogen and requires the activation of platelets plus the binding of fibrinogen. The extent of aggregation was assessed by platelet reaction units (PRU), determined by the VerifyNow P2Y12 assay. The VerifyNow P2Y12 assay is designed to direct

Prasugrel/Clopidogrel Reference (6 or 5.5 hrs)

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	8.0	± 8.7
Clopidogrel Within 5 Min Post Cangrelor	159.0	± 72.7
Clopidogrel 1.5 Hrs During Cangrelor	211.3	± 66.8
Clopidogrel 1 Hr During Cangrelor	197.3	± 15.0

2.25 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	76.7	± 23.7
Clopidogrel Within 5 Min Post Cangrelor	99.0	± 27.6
Clopidogrel 1.5 Hrs During Cangrelor	90.3	± 32.3
Clopidogrel 1 Hr During Cangrelor	98.7	± 19.6

2.5 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	208.0	± 30.2
Clopidogrel Within 5 Min Post Cangrelor	220.7	± 11.6
Clopidogrel 1.5 Hrs During Cangrelor	229.8	± 24.6
Clopidogrel 1 Hr During Cangrelor	206.3	± 26.9

2.75 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	225.7	± 42.5
Clopidogrel Within 5 Min Post Cangrelor	233.0	± 21.7
Clopidogrel 1.5 Hrs During Cangrelor	255.8	± 43.7
Clopidogrel 1 Hr During Cangrelor	214.3	± 11.9

3 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	226.0	± 28.5
Clopidogrel Within 5 Min Post Cangrelor	215.7	± 35.0
Clopidogrel 1.5 Hrs During Cangrelor	234.5	± 34.2
Clopidogrel 1 Hr During Cangrelor	212.7	± 10.3

4 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	77.0	± 126.5
Clopidogrel Within 5 Min Post Cangrelor	182.0	± 82.3
Clopidogrel 1.5 Hrs During Cangrelor	215.5	± 67.4
Clopidogrel 1 Hr During Cangrelor	203.7	± 11.2

5.5 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	24.5	± 34.6
Clopidogrel Within 5 Min Post Cangrelor	155.0	± 69.8
Clopidogrel 1.5 Hrs During Cangrelor	NA	± NA
Clopidogrel 1 Hr During Cangrelor	NA	± NA

Extent of Preservation of Platelet Inhibitory Effect of Cangrelor Treatment After Prasugrel or Clopidogrel Compared to Treatment With Cangrelor Alone Determined By VerifyNow P2Y12 Assay Secondary · Day 1 at 1, 1.5, 2, or 2.5 hrs after administration of prasugrel or clopidogrel (reference) and Day 1 at 1.75 and 2 hrs after initiation of cangrelor infusion

A reference point for cangrelor was chosen for comparison and designated as the administration time of prasugrel 60 mg or clopidogrel 600 mg (2.5, 2, 1.5, or 1 hrs). Platelet function was assessed using the VerifyNow P2Y12 assay. The VerifyNow P2Y12 assay measures the aggregation or cross linking of platelets by fibrinogen and requires the activation of platelets plus the binding of fibrinogen. The extent of aggregation was assessed by PRU, determined by the VerifyNow P2Y12 assay. The VerifyNow P2Y12 assay is designed to directly measure the effects of drugs on the P2Y12 receptor, using prosta

Cangrelor Reference (2.5, 2, 1.5, or 1 hrs)

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	208.0	± 30.2
Clopidogrel Within 5 Min After Cangrelor	7.3	± 5.1
Clopidogrel 1.5 Hrs During Cangrelor	17.7	± 18.2
Clopidogrel 1 Hr During Cangrelor	7.0	± 2.0

1.75 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	3.3	± 2.3
Clopidogrel Within 5 Min After Cangrelor	3.7	± 2.1
Clopidogrel 1.5 Hrs During Cangrelor	25.0	± 30.5
Clopidogrel 1 Hr During Cangrelor	6.3	± 1.5

2 hrs

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	5.3	± 2.1
Clopidogrel Within 5 Min After Cangrelor	NA	± NA
Clopidogrel 1.5 Hrs During Cangrelor	28.8	± 18.2
Clopidogrel 1 Hr During Cangrelor	5.7	± 2.1

Bleeding Events In Accordance With GUSTO Scale Secondary · Screening through the follow-up period (5 to 7 days after Day 1)

Bleeding was assessed by history, physical exam, and complete blood count (CBC) that was performed on study Day 1. Reports of bleeding were to be evaluated by performance of a CBC. Participants were assessed for bleeding events in accordance with the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) scale. The severity of bleeding events by GUSTO Criteria is defined as the following: * Severe/life-threatening: fatal, intracranial hemorrhage, or if hemodynamic compromise results * Moderate: transfusion required * Mild: no transfusion or hemodynamic compromise A summary of s

Mild

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	0
Clopidogrel Within 5 Min After Cangrelor	0
Clopidogrel 1.5 Hrs During Cangrelor	0
Clopidogrel 1 Hr During Cangrelor	0

Moderate

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	0
Clopidogrel Within 5 Min After Cangrelor	0
Clopidogrel 1.5 Hrs During Cangrelor	0
Clopidogrel 1 Hr During Cangrelor	0

Life-threatening/Severe

Group	Value	95% CI
Prasugrel 30 Min After Cangrelor	0
Clopidogrel Within 5 Min After Cangrelor	0
Clopidogrel 1.5 Hrs During Cangrelor	0
Clopidogrel 1 Hr During Cangrelor	0

Sponsor's own description

There are two separate objectives in this study: 1. To demonstrate the pharmacodynamic (PD) profile when participants treated with cangrelor are switched to oral prasugrel 60 mg administered 30 minutes (min) after cangrelor infusion is discontinued 2. To demonstrate the PD profile when participants treated with cangrelor are switched to oral clopidogrel 600 mg administered during or immediately after cangrelor infusion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cangrelor

Trials testing the same drug.

NCT06792643 — Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest rece · Phase 2 · recruiting
NCT05505591 — Intravenous CAngrelor in High-bleeding Risk Patients Undergoing percutaneouS Coronary Intervention (ICARUS) Registry · unknown
NCT04667078 — REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke pat · Phase 3 · recruiting
NCT04790032 — Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry) · completed
NCT04668144 — Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI · Phase 4 · completed

Other recruiting trials for Coronary Artery Disease (CAD)

Currently open trials in the same condition.

NCT07479433 — The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI · recruiting
NCT07349875 — Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial · Phase 4 · recruiting
NCT07277686 — AI Facial Analysis Algorithm to Screening Coronary Artery Disease in High-Risk Community Population · recruiting
NCT07148518 — Comparison of Upper and Lower Limb Maximal Exercise Capacities and Arterial Stiffness in Patients With CAD · recruiting
NCT07392021 — Effects of a Recovery-Promoting Program in Patients Undergoing CABG Surgery · NA · active not recruiting

Other The Medicines Company trials

Trials by the same sponsor.

NCT03399370 — Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol · Phase 3 · completed
NCT03397121 — Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Het · Phase 3 · completed
NCT03400800 — Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol · Phase 3 · completed
NCT03159416 — A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7 · Phase 1 · completed
NCT02925416 — Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Struct · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01979445 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Medicines Company
Last refreshed: 26 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01979445.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing